<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828971</url>
  </required_header>
  <id_info>
    <org_study_id>12670</org_study_id>
    <secondary_id>2007-001491-36</secondary_id>
    <nct_id>NCT00828971</nct_id>
  </id_info>
  <brief_title>A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs</brief_title>
  <acronym>MERAK</acronym>
  <official_title>A Prospective, Randomized, Open Label, Active Comparator, Multicenter, National Trial to Compare the Efficacy and Safety of Sequential IV/PO Moxifloxacin 400 mg Once Daily Versus IV Amoxicillin/Clavulanate 2,0/0,2 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanate 875/125 mg Every 8 Hours in the Treatment of Adult Subjects With Complicated Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is
      as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment
      of complicated skin and skin structure infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response up to 14-21 days after the completion of study drug therapy (Test-of-Cure visit [TOC]).</measure>
    <time_frame>Test-of-Cure visit [TOC].</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response assessed by the investigator on treatment Day 3-5</measure>
    <time_frame>Day 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response assessed by the investigator at the end-of-therapy (EOT).</measure>
    <time_frame>At the end-of-therapy (EOT)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to switch from oral to IV therapy</measure>
    <time_frame>Day of switch from oral to IV therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological response (for microbiologically valid population) at the EOT and TOC</measure>
    <time_frame>At the end-of-therapy (EOT), Test-of-Cure visit [TOC].</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Infectious Diseases</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelox (Moxifloxacin, BAY12-8039)</intervention_name>
    <description>Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicilline/clavulanic</intervention_name>
    <description>IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Men or women of age &gt;/= 18 years with a diagnosis of bacterial skin and skin structure
             infection that requires

               -  Hospitalization

               -  Initial parenteral therapy for at least 48 hours

          -  Complicated by at least one of the following criteria:

               -  Involvement of deep soft tissues (e.g. fascial, muscle layers)

               -  Requirement for a significant surgical intervention including surgical drainage,
                  drainage procedure guided by imaging and/or debridement

               -  Association with a significant underlying disease that may complicate response to
                  treatment.

               -  Presence of SIRS (Systemic Inflammatory Response Syndrome) defined as two or more
                  of the following signs or symptoms: - temperature &gt; 38.3°C or &lt; 36°C - white
                  blood cell count &gt; 12.000/mmc or &lt; 4.000 or &gt; 10% bands - pulse rate &gt; 90
                  beats/min - respiratory rate &gt; 20178 - systolic blood pressure &lt;/= 90 mmgHg -
                  decreased capillary refill/mottling &gt; 2 seconds - lactate &gt; 2 mmol/L - altered
                  mental status - hyperglycemia &gt; 120 mg/dl or 7.7 mmol/L in the absence of
                  diabetes - protein C (CPR) &gt; 20 mg/L (VR 0-5)3. Duration of infection &lt; 21 days

          -  Diagnosis of one of the following skin and skin structure infections:

               -  major abscess(es) associates with extensive cellulitis

               -  erysipelas and cellulitis

               -  infected pressure ulcers(s)

               -  wound infections including: post surgical (surgical incision), post traumatic,
                  human bite/clenched fist and animal bite wound and wound associated with
                  injection drug abuse

               -  Infected ischemic ulcers with at least one of the following conditions: -
                  Diabetes mellitus - Peripheral vascular disease - Conditions pre-disposing to
                  pressure scores such as paraplegia or peripheral neuropathy

          -  Presence of at least 3 of the following local signs and symptoms

               -  purulent drainage or discharge

               -  erythema extended &gt;1 cm from the wound edge

               -  fluctuance

               -  pain or tenderness to palpation

               -  swelling or induration

               -  fever defined as body temperature &gt; 37.5°C (axillary), &gt; 38°C (orally), &gt; 38.5°C
                  (tympanically), or &gt; 39°C (rectally). OR Elevated total peripheral white blood
                  cell (WBC) count&gt; 12,000/mm3 OR &gt; 15% immature neutrophils (blends) regardless of
                  total peripheral WBC count

               -  C-reactive protein (CRP) &gt;20 mg/L

        Exclusion Criteria:

          -  Women, who are pregnant or lactating, or in whom pregnancy can not be excluded (Note:
             a urine pregnancy test has to be performed for all women of childbearing potential
             before randomization to the study drug).

          -  The following skin and skin structure infections:

               -  Necrotizing fasciitis including Fournier's gangrene, ecthyma gangrenosum,
                  streptococcal necrotizing fasciitis and clostridial necrotizing fasciitis.

               -  Burn wound infections.

               -  Secondary infections of a chronic skin disease (eg, atopic dermatitis).

               -  Infection of prosthetic materials. Subjects with removal of a prosthetic device
                  involved in an infection should not be included.

               -  Infections where a surgical procedure alone is definitive therapy.

               -  Subjects with uncomplicated skin and skin structure infections including
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bagno di Ripoli</city>
        <state>Firenze</state>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <zip>06122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complicated skin and skin structure infections</keyword>
  <keyword>cSSSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

